Combination therapy shows high success rate

Share on Pinterest
A combination approach to treating prostate cancer may be the best way forward, according to new research. Image credit: MirageC/Getty Images.
  • Prostate cancer is a type of cancer that can lead to death.
  • The exact treatment for prostate cancer will depend on the person and the severity of the cancer.
  • Researchers are still working to improve treatment options for prostate cancer.
  • A recent study found that the combined use of three different therapies improved survival rates in men with prostate cancer.

Cancer affects people all over the world. Experts are constantly evaluating how different treatments can eliminate or slow the spread of cancer

Each type of cancer is different, which leads to the development of various methods of treatment and detection.

A recent study published in The Lancet found that a specific combination treatment could improve the survival rate of men with prostate cancer.

Prostate cancer is one of the most common types of cancer in men. As noted by the Centers for Disaster Control and Prevention (CDC), in 2018 there were more than 210,000 new cases of prostate cancer and nearly 31,500 people with prostate cancer died from it.

As noted by the American Cancer Society, a few different methods can help detect prostate cancer. One is to do a prostate-specific antigen (PSA) blood test.

If the PSA level is above a specific benchmark, it may indicate prostate cancer. However, there are other reasons why the PSA level is high, so it is not a definitive diagnostic tool.

Doctors may also do a digital rectal examination to feel the prostate and note any abnormal masses. To confirm the results of an elevated PSA or abnormal digital rectal exam, doctors will order a prostate biopsy. If this confirms the presence of prostate cancer, treatment can begin.

Treatment for prostate cancer may include one or more options, such as surgery, radiation therapy, cryotherapy, hormone therapy, immunotherapy, and chemotherapy. Researchers are still working to improve treatment options and survival rates for people with prostate cancer.

The study in The Lancet was a randomized controlled trial. The researchers divided men with prostate cancer into three separate treatment groups.

The study included participants who had previously had to have their prostate removed and who had a certain level of PSA after prostate removal. A total of 1,792 participants enrolled in the study.

Researchers sought to find out whether using a specific, combined treatment method increased survival rates and decreased the progression of severe cancer.

They used the label “lack of progress”. The three treatment groups included the three different treatment methods:

  • group 1 received a form of radiation therapy called prostatic bed salvage radiation therapy (PBRT), which specifically targets the prostate region after removal of the prostate
  • group 2 received the same radiation as group 1 (PBRT) and also received short-term androgen deprivation therapy (ADT)which works to suppress certain hormones to decrease fuel for prostate cancer cells
  • group 3 received the same treatments as group 2, with the addition of an additional component: this group received PBRT, ADT, and pelvic lymph node radiation therapy (PLNRT), a type of radiation that explicitly targets the lymph nodes from the pelvic area, where the prostate is located, the cancer can spread.

The study found that the absence of progression after 5 years was highest for those in group 3. In group 1, almost 71% of the group were free of progression. In group 3, the percentage was 87.4%.

These results indicate that adding short-term androgen deprivation therapy and pelvic lymph node radiation therapy to salvage prostate bed radiation therapy may help improve survival rates in people with prostate cancer. Prostate cancer.

Author of the study Dr. Alan Pollack noted the following highlights for Medical News Today:

“This is the first randomized study to demonstrate the added benefit of adding pelvic lymph node therapy to androgen deprivation therapy and standard prostate bed therapy. This is a three-arm study designed to test treatment intensification from standard prostate bedside RT (PBRT), PBRT plus short-term androgen deprivation therapy (STADT), and PBRT plus STADT plus pelvic lymph node therapy (PLNRT). The primary endpoint was no progression at 5 years [and the study] showed that overall there were additional gains with the addition of ADT and then further gains with PLNRT.

The study authors note that using this combination treatment method is not without risks. They point out that it could increase the risk of certain bone marrow problems. They also note that a longer follow-up time would be necessary to confirm the full effectiveness of the treatment.

Dr. Kelvin Mosesdirector of the Comprehensive Prostate Cancer Clinic at Vanderbilt University Medical Center, who was not involved in this study, agreed that more follow-up research was needed, but said the results so far are promising.

He explained for DTM this “[t]his study reinforces the importance of pelvic lymph node control either at the time of surgery or in the setting of post-prostatectomy recurrence.

He added that “[i]Whether the benefit of progression translates to reduced prostate cancer metastasis or death remains to be seen, but these results are promising and may change the paradigm for the treatment of biochemical recurrences.

The study authors further note that as prostate imaging improves, it will impact how this treatment method is applied. But the research provides overall encouraging results that survival rates can improve for people with prostate cancer with the right kind of treatment.

Dr Hayley Whitakeran oncologist from the University College of London, who was not involved in this study, was enthusiastic about its results:

“There are many ways to treat patients with prostate cancer, but the order in which different treatments are used or the combination of different treatments offers enormous potential for prolonging [the] the life of men for several years.

According to her, “[t]This is groundbreaking research that has the potential to have a real impact on men being treated for prostate cancer by making significant advances in the combination of surgery, radiation therapy and hormone treatments.

Comments are closed.